You are here

Article Text

Article menu
Download PDFPDF
Letter
Letter to the Editor regarding “Ophthalmic artery angioplasty for age-related macular degeneration”
  1. Andrea Servillo,
  2. Riccardo Sacconi,
  3. Nicolò Ribarich,
  4. Giuseppe Querques
  1. Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy
  1. Correspondence to Professor Giuseppe Querques, Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, 20132 Milano, Italy; giuseppe.querques{at}hotmail.it

https://doi.org/10.1136/neurintsurg-2022-018750

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the retrospective study by Lylyk et al on the use of ophthalmic artery (OA) angioplasty in patients with age-related macular degeneration (AMD).1

    With the premise in mind that AMD is correlated with a compromised blood flow in the ocular pathway, the authors selected five patients with clinically significant late-stage AMD with profound vision loss in one or both eyes suitable for the compassionate use of OA angioplasty.1 The authors carefully described the OA angioplasty procedure that was performed successfully in all patients despite some difficulties relating to the acute take-off angle of the OA, partial restriction of the OA ostium, and challenging device performance.1 The results reported by the authors were a gain in visual acuity in all patients at the follow-up visit.1 We greatly appreciate the effort of the authors in performing this study since theirs is the first known publication describing the use …

    View Full Text

    Footnotes

    • Contributors AS: writing-original draft. RS: writing-review and editing. NR: writing-original draft. GQ: writing-review and editing.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests GQ is a consultant for Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc. (Irvine, California, USA), Bayer Schering Pharma (Berlin, Germany), Heidelberg Engeneering (Germany), Novartis (Basel, Switzerland), Sandoz (Berlin, Germany), Zeiss (Dublin, California, USA).

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

    Linked Articles